Differences in main characteristics of elderly patients with CKD experiencing the composite renal outcome (CKD progressors) as compared with others (non-progressors)
| CKD progressors (N=30; 9.86%) | Non-progressors (N=274; 90.1%) | p value | |
| Age (years) | 71±8 | 68±5 | 0.22 |
| Male sex, n (%) | 17 (56.6) | 177 (64.5) | 0.39 |
| BMI (kg/m2) | 29.2±4.0 | 25.3±6.1 | 0.04 |
| Systolic blood pressure (mm Hg) | 144±21 | 139±26 | 0.16 |
| Diastolic blood pressure (mm Hg) | 81±16 | 75±12 | 0.12 |
| Diabetes, n (%) | 20 (66.6) | 143 (52.1) | 0.10 |
| Total cholesterol (mg/dL) | 171±44 | 135±39 | 0.01 |
| HDL cholesterol (mg/dL) | 52±13 | 51±22 | 0.55 |
| LDL cholesterol (mg/dL) | 133.4±46.7 | 106.4±38.8 | 0.03 |
| Hemoglobin (g/dL) | 12.8±2.7 | 13.0±2.1 | 0.61 |
| eGFR (mL/min/1.73 m2) | 49.5±22.1 | 66.3±19.2 | 0.13 |
| Creatinine (mg/dL) | 1.76±0.71 | 1.49±0.88 | 0.19 |
| Glycemia (mg/dL) | 138±15 | 110±13 | 0.04 |
| Proteinuria (g/24 hours) | 0.4 (0.1–0.9) | 0.4 (0.01–0.6) | 0.32 |
| Urinary sodium (mg/24 hours) | 133±37 | 129±39 | 0.27 |
| Vitamin D (mcg/dL) | 24.9±14.0 | 23.7±11.8 | 0.46 |
| Statins use, n (%) | 16 (53) | 111 (40.5) | 0.17 |
| ESAs use, n (%) | 7 (23.3) | 30 (10.9) | 0.05 |
| Antihypertensive drugs | |||
| Diuretics, n (%) | 12 (40) | 80 (29.9) | 0.22 |
| Beta-blockers, n (%) | 7 (23.3) | 38 (13.8) | 0.16 |
| ARBs, n (%) | 20 (66.6) | 156 (56.9) | 0.30 |
| ACEi, n (%) | 23 (76.6) | 232 (84.6) | 0.25 |
| CCBs, n (%) | 8 (26.6) | 69 (25.1) | 0.85 |
| History of CV disease, n (%) | 29 (97) | 226 (82) | 0.04 |
| Etiology of CKD, n (%) | |||
| Nephrosclerosis | 16 (53) | 204 (74.4) | 0.01 |
| Other | 14 (47) | 70 (25.6) |
ACEi, angiotensin converting enzyme-inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CCBs, calcium channel blockers; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESAs, erythropoietin-stimulating agents; HDL, high density lipoproteins; LDL, low density lipoproteins.